February 8, 2017
Zealand gets $3.3M from Sanofi’s sales of Lyxumia
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.